On February 6, 2026, William D. Waddill, a director at Protagonist Therapeutics (NASDAQ: PTGX), executed a notable insider transaction that offers insight into how company leadership navigates market opportunities. Waddill exercised stock options and immediately divested 20,000 shares, netting